Maze Therapeutics (MAZE) CEO awarded 150,000 options and 75,000 RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics, Inc. reported that Chief Executive Officer Jason V. Coloma received new equity awards. He was granted a stock option for 150,000 shares with a zero exercise price shown in the filing, vesting in 1/48 monthly tranches starting on April 1, 2026, as long as he remains in service.

Coloma was also granted 75,000 restricted stock units, each representing the right to receive one share of common stock upon settlement. These RSUs vest in four equal annual installments, with the first 1/4 vesting on March 1, 2027 and the remaining tranches vesting on each anniversary, subject to continued service. The RSUs do not expire; they either vest or are cancelled before vesting.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Coloma Jason V

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	150,000	$0.00	--
Grant/Award	Restricted Stock Units	75,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 shares (Direct); Restricted Stock Units — 75,000 shares (Direct)

Footnotes (1)

The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$45.61	03/02/2026		A		150,000		⁽¹⁾	03/01/2036	Common Stock	150,000	$0	150,000	D
Restricted Stock Units	⁽²⁾	03/02/2026		A		75,000		⁽³⁾	⁽⁴⁾	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

3. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

4. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Maze Therapeutics (MAZE) CEO Jason Coloma receive?

Maze Therapeutics granted CEO Jason Coloma a stock option for 150,000 shares and 75,000 restricted stock units. The option vests monthly over four years, while the RSUs vest annually in four equal installments, all conditioned on his continued service with the company.

How do the new stock options for Maze Therapeutics (MAZE) CEO vest?

The 150,000-share stock option for Maze Therapeutics’ CEO vests in 1/48 monthly increments. The first tranche vests on April 1, 2026, and additional portions vest each month thereafter, provided he continues to serve the company on each scheduled vesting date.

What is the vesting schedule for Maze Therapeutics (MAZE) CEO’s restricted stock units?

The 75,000 restricted stock units vest in four equal installments of 1/4 each. The first tranche vests on March 1, 2027, with the remaining portions vesting on each one-year anniversary, assuming the CEO continues his service with Maze Therapeutics through each vesting date.

What does each Maze Therapeutics (MAZE) restricted stock unit represent for the CEO grant?

Each restricted stock unit in the CEO’s award represents a contingent right to receive one share of Maze Therapeutics common stock. The units convert into shares only upon vesting and settlement, and may be cancelled if vesting conditions tied to continued service are not satisfied.

Do the Maze Therapeutics (MAZE) restricted stock units granted to the CEO expire?

The restricted stock units granted to the CEO do not have a traditional expiration date. According to the disclosure, they either vest according to the specified schedule or are cancelled before the vesting date if the required continued service conditions are not met.

Is the Maze Therapeutics (MAZE) CEO equity grant a purchase or an award?

The CEO transactions are classified as grant or award acquisitions, not open-market purchases. The filing uses transaction code “A,” indicating equity awards granted by the company as compensation rather than shares bought or sold on the public market.